Skip to contentC
CNBX Pharmaceuticals Inc.
C
CNBXCNBX Pharmaceuticals Inc. Q2 2014 · 10-Q
Revenue$0.00$0.00no prior Q2 2013 on file Net Income-$55.35K-$55.35KN/M vs Q2 2013 EPS Diluted$0.00$0.00— vs Q2 2013 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CNBX Pharmaceuticals Inc. · CIK 1343009 · Engraved from SEC EDGAR
Operating Cash Flowderived-$55,170— Free Cash Flowderived-$55,170— ended Feb 28, 2015 · filed Apr 20, 2015 · 51 d after period end